OPTIMISING PHARMACEUTICAL
CONTRACT OUTSOURCING Siegfried is a global leader in process development for specialised products and customised contract manufacturing services to the pharmaceutical industry. Philip Yorke spoke to Marianne Spaene, the company’s EVP of sales, marketing and global business development, about its unique out-licensed portfolio and the global trend towards high-potency products.
S
iegfried was founded in 1873 by pharmacist Samuel Benoni Siegfried, who began by supplying medical products to pharmacies. From the outset it was a success and by 1904 it was converted to a joint-stock company and was subsequently listed on the Swiss Stock Exchange in 1973. In the late 1980s the company transformed itself into a leading CMO player. Today it is a truly global organisation with a unique range of contract production capabilities and services that cover chemistry, continuous flow technology and formulation technologies, as well as micronisation and spray drying technologies. In addition, Siegfried offers a range of fully integrated services along the entire supply chain, as
well as services relating to regulatory affairs, intellectual property, project management, packaging and logistics. As a preferred partner to more than 60 per cent of the world’s pharmaceutical companies, manufacturers both large and small rely on Siegfried’s long-standing pharmaceutical and chemical heritage as well as its in-depth knowledge of drug production and licensing. Furthermore, as a global company serving pharmaceutical manufacturers worldwide, Siegfried has continued to invest in new manufacturing capabilities. More recently, investment has been focused on additional technologies in the US and Zofingen and in the expansion at its drug product manufac-
turing facility in Malta. This is in addition to establishing a manufacturing presence in Asia, by which the company plans to gain a competitive edge in its CMO business.
Increased potency products In the fast changing world of pharmaceuticals, the demand for drugs with higher potency levels and pharmacological activity shows no sign of abating. Since 2004 Siegfried has continually invested in advanced ‘containment technology’ to offset the potential occupational health hazards and possible threats to the environment of these ‘super-drugs’. However, the company’s significant investment in special containment measures ensures safe
Industry Europe 205
